^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.01-032 - Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Published date:
07/12/2022
Excerpt:
EGFR mutations exhibited a median progression-free survival of 6.7 months (95% CI, 2.4, 11.0), a median overall survival of 20.0 months (95% CI, 3.6, 36.4). Moreover, patients carrying EGFR Ex20ins showed similar ORR/DCR and PFS with other mutation patterns (ORR: 36.4% [4/11] vs. 37.5% [3/8], p=1.00; DCR: 90.9% [10/11] vs. 75.0% [6/8], p=0.348, PFS: 4.3 vs. 7.1 months, p=0.327)...Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations.
Source:
Title:
Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study
Published date:
03/23/2022
Excerpt:
Among enrolled patients, twelve cases had EGFR Ex20ins and remaining nine cases had EGFR other mutations such as L861Q, G719A, and G709T. Patients harboring uncommon EGFR mutations exhibited a median progression-free survival of6.7 months (95% CI, 2.4, 11.0), and the 6-month PFS rate was 52.4%. Moreover, of the nineteen patients evaluable for efficacy, the objective response rate (ORR) was 36.8%(7/19), and the disease control rates (DCR) was 84.2% (16/19). Notably, patients carrying EGFR Ex20ins showed similar ORR/DCR and PFS with other mutation patterns(ORR: 36.4% [4/11] vs. 37.5% [3/8], p¼1.00; DCR: 90.9% [10/11] vs. 75.0% [6/8],p¼0.348, PFS: 4.3 vs. 7.1 months, p¼0.327). Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations.
Trial ID:
